HCM
ALNY icon

Highline Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Highline Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-158,669
Closed -$11.6M – 37
2018
Q4 		$11.6M Buy
+158,669
New +$12.2M 0.78% 31

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Highline Capital Management's ALNY Position: Q1 2019 in Review

Highline Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2019, closing a stake of 158,669 shares — an estimated $11.6M sold.

Highline Capital Management first reported a position in ALNY in Q4 2018 and held it in 1 quarter. The position peaked at $11.6M in Q4 2018. 290 funds tracked by Wall St. Rank hold ALNY as of Q1 2019.

  • Highline Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2019 after selling out during the quarter.
  • Highline Capital Management sold 158,669 Alnylam Pharmaceuticals shares in Q1 2019, an estimated $11.6M.
  • Highline Capital Management first reported a position in Alnylam Pharmaceuticals in Q4 2018 and held it in 1 quarter.
  • Highline Capital Management's Alnylam Pharmaceuticals position peaked at $11.6M in Q4 2018.
  • 290 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2019.

Based on Highline Capital Management's 13F filing for Q1 2019, filed 15 May 2019.